<DOC>
	<DOCNO>NCT02095990</DOCNO>
	<brief_summary>To assess ability new 4 % Hydroquinone formulation ( Melanoderm 4 % Crema ) reduce melasma face , use split-face randomization design , evaluate MASI Score baseline week 4 week 8 , half-faces receive active treatment vs. placebo . To assess tolerance new 4 % Hydroquinone formulation ( Melanoderm 4 % Crema ) face . To assess patient ' satisfaction regard Melanoderm 4 % Crema 8 week .</brief_summary>
	<brief_title>Efficacy Safety 4 % Hydroquinone Cream ( Melanoderm 4 % ) Treatment Melasma : Randomized Controlled Split-face Study</brief_title>
	<detailed_description />
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Adult woman age 1865 year old . Fitzpatrick phototypes I IV . Presenting moderate severe facial melasma facial , basal Melasma Area Severity Index ( MASI Index ) 10 20 . Women childbearing potential must use adequate contraceptive method avoid pregnancy must negative pregnancy test maximum 72 hour receive trial treatment . Breastfeeding woman include study . Having give freely expressly informed consent . Those history allergy hypersensitivity cosmetic product , hydroquinone , one ingredient investigational product . Fitzpatrick phototype V. Skin pigmentation diseases different melasma . Evidence active cancer disease diagnosis cancer last year . Those receive topical oral treatment could interfere melasma . Pregnant breastfeed woman , expect get pregnant study . Evidence suspicion low compliance study visit procedure . Participation clinical trial simultaneously previous 3 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Facial Melasma</keyword>
</DOC>